Dementia in Parkinson's disease

Current Treatment Options in Neurology

Volumn 13, Issue 3, 2011, Pages 242-254

  Kurtz, Avrom L ^a   Kaufer, Daniel I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBIDOPA; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLOZAPINE; DIPHENHYDRAMINE; DONEPEZIL; FLUDROCORTISONE; GABAPENTIN; GALANTAMINE; HALOPERIDOL; LEVODOPA; MELATONIN; MEMANTINE; MIDODRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYBATE SODIUM; PAROXETINE; PEMETREXED; PLACEBO; PYRIDOSTIGMINE; QUETIAPINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VENLAFAXINE; YOHIMBINE;

ABDOMINAL CRAMP; AGRANULOCYTOSIS; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; ATRIOVENTRICULAR BLOCK; AUTONOMIC DYSFUNCTION; BEDTIME DOSAGE; BRADYCARDIA; BRONCHOSPASM; CATAPLEXY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; COST BENEFIT ANALYSIS; DAYTIME SOMNOLENCE; DELUSION; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; EVENING DOSAGE; FATIGUE; FLATULENCE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERSALIVATION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IRRITABILITY; KINESIOTHERAPY; LEUKOPENIA; LOW DRUG DOSE; MOOD DISORDER; MORNING DOSAGE; MOTOR DYSFUNCTION; MUSCLE CRAMP; NARCOLEPSY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PHYSIOTHERAPY; PRESYNCOPE; PSYCHOMOTOR DISORDER; PSYCHOSIS; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SLEEP THERAPY; SOMNOLENCE; SPEECH THERAPY; TACHYCARDIA; TREATMENT DURATION; TREMOR; VISUAL HALLUCINATION; VIVID DREAM; VOMITING; WEIGHT REDUCTION;

EID: 79955818964     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-011-0121-1     Document Type: Article

References (54)

1. CF Lippa JE Duda M Grossman, et al. 2007 DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers Neurology 68 812 19 17353469 10.1212/01.wnl.0000256715.13907.d3 1:CAS:528:DC%2BD2sXisFyhu70%3D (Pubitemid 46568532)
2. D Aarsland K Andersen JP Larsen A Lolk P Kragh-Sorensen 2003 Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study Arch Neurol 60 387 392 12633150 10.1001/archneur.60.3.387 (Pubitemid 36314364)
3. M Emre D Aarsland R Brown, et al. 2007 Clinical diagnostic criteria for dementia associated with Parkinson's disease Mov Disord 22 1689 1707 17542011 10.1002/mds.21507 (Pubitemid 47597592)
4. IG McKeith D Galasko K Kosaka, et al. 1996 Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop Neurology 47 1113 1124 8909416 1:STN:280:DyaK2s%2FmsF2gtw%3D%3D (Pubitemid 26374873)
5. IG McKeith DW Dickson J Lowe, et al. 2005 Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology 65 1863 1872 16237129 10.1212/01.wnl.0000187889.17253.b1 1:STN:280: DC%2BD2Mnpt1GqsQ%3D%3D (Pubitemid 43970103)
6. D Collerton D Burn I McKeith J O'Brien 2003 Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia Dement Geriatr Cog Disord 16 229 37 10.1159/000072807 (Pubitemid 37188118)
7. CC Janvin JP Larsen DP Salmon, et al. 2006 Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease Mov Disord 21 337 42 16211595 10.1002/mds.20726
8. K Bronnick M Emre R Lane 2007 Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease J Neurol Neurosurg Psychiatry 78 1064 1068 17287236 10.1136/jnnp.2006.108076
9. MF Folstein SE Folstein PR McHugh 1975 "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 3 189 98 10.1016/0022-3956(75)90026-6
10. DI Kaufer SC Williams AJ Braaten K Gill S Zimmerman PD Sloane 2008 Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of three tests J Am Med Dir Assoc 9 586 93 19083293 10.1016/j.jamda.2008.05.006
11. ZS Nasreddine NA Phillips V Bédirian S Charbonneau V Whitehead I Collin JL Cummings H Chertkow 2005 The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment J Am Geriatr Soc 53 695 699 15817019 10.1111/j.1532-5415.2005.53221.x (Pubitemid 41623495)
12. S Nazem AD Siderowf JE Duda, et al. 2009 Montreal Cognitive Assessment performance in patients with Parkinson's disease with "normal" global cognition according to Mini-Mental State Examination score J Am Geriatr Soc 57 304 308 19170786 10.1111/j.1532-5415.2008.02096.x The MoCA is an increasingly accepted screening test for PDD that provides a more robust assessment of executive and visuospatial functions than the MMSE.
13. B Dubois D Burn C Goetz, et al. 2007 Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society task force Mov Disord 16 2314 2324 10.1002/mds.21844 (Pubitemid 351155975)
14. IG McKeith T Del Ser P Spano, et al. 2000 Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study Lancet 356 2031 2036 11145488 10.1016/S0140-6736(00)03399-7 1:CAS:528:DC%2BD3MXnvV2r (Pubitemid 32009817)
15. M Emre D Aarsland A Albanese, et al. 2004 Rivastigmine for dementia associated with Parkinson's disease N Engl J Med 351 2509 2518 15590953 10.1056/NEJMoa041470 1:CAS:528:DC%2BD2cXhtVGksbnF (Pubitemid 39603164)
16. D Aarsland K Laake JP Larsen C Janvin 2002 Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study J Neurol Neurosurg Psychiatry 72 708 712 12023410 10.1136/jnnp.72.6.708 1:STN:280:DC%2BD383os12rsw%3D%3D (Pubitemid 34557010)
17. I Leroi J Brandt SG Reich, et al. 2004 Randomized trial of donepezil in cognitive impairment in Parkinson's disease Int J Geriatr Psychiatry 19 1 8 14716693 10.1002/gps.993 (Pubitemid 38180686)
18. B Ravina M Putt A Siderowf, et al. 2005 Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study J Neurol Neurosurg Psychiatry 76 934 9 15965198 10.1136/jnnp.2004.050682 1:STN:280:DC%2BD2Mzhs1Cltg%3D%3D (Pubitemid 40909549)
19. K Edwards D Royall, et al. 2007 Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study Dem Geriatr Cog Disord 23 401 405 10.1159/000101512 1:CAS:528:DC%2BD2sXmt1Sqsb8%3D (Pubitemid 46897177)
20. D Aarsland C Ballard Z Walker, et al. 2009 Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial Lancet Neurol 8 613 618 19520613 10.1016/S1474-4422(09)70146-2 1:CAS:528:DC%2BD1MXovVCitLc%3D
21. M Emre M Tsolaki U Bonuccelli, et al. 2010 on behalf of the 11018 Study Investigators. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial Lancet Neurol 10 969 977 10.1016/S1474-4422(10)70194-0 This study importantly illustrates the potential beneficial effect of memantine on behavioral and global improvement in DLB
22. RE Tractenberg CM Singer JA Kaye 2005 Symptoms of sleep disturbance in persons with Alzheimer's disease and the normal elderly J Sleep Res 14 177 85 15910515 10.1111/j.1365-2869.2005.00445.x (Pubitemid 40813586)
23. BF Boeve CB Saper 2006 REM sleep behavior disorder; a possible early marker for synucleinopathies Neurology 66 796 7 16567693 10.1212/01.wnl. 0000209264.61035.bb (Pubitemid 43739749)
24. CH Schenck MW Mahowald 2002 REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in Sleep Sleep 25 120 38 11902423 (Pubitemid 34193575)
25. CH Schenck SR Bundlie MG Ettinger MW Mahowald 1986 Chronic behavioral disorders of human REM sleep: a new category of parasomnia Sleep 9 293 308 3505730 1:STN:280:DyaL1M7hsVSktg%3D%3D (Pubitemid 18020420)
26. RN Aurora RS Zak RK Maganti, et al. 2010 Best practice guide for the treatment of REM sleep behavior disorder (RBD). American Academy of Sleep Medicine J Clin Sleep Med 61 85 95
27. B Boeve M Silber T Ferman 2003 Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients Sleep Med 4 281 284 14592300 10.1016/S1389-9457(03)00072-8 (Pubitemid 36974807)
28. V Larsson D Aarsland, et al. 2010 The effect of memantine on sleep behavior in dementia with Lewy bodies and Parkinson's disease dementia Int J Geriatr Psychiatry 25 1030 1038 20872929 10.1002/gps.2506
29. B Hogl B Saletu, et al. 2002 Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial Sleep 25 905 9 12489899 1:STN:280:DC%2BD38jislWktA%3D%3D (Pubitemid 35424536)
30. CH Adler JN Caviness JG Hentz, et al. 2003 Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease Mov Disord 18 287 93 12621632 10.1002/mds.10390 (Pubitemid 36410825)
31. WG Ondo R Fayle F Atassi, et al. 2005 Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial J Neurol Neurosurg Psychiatry 76 1636 9 16291885 10.1136/jnnp.2005.065870 1:STN:280:DC%2BD2MnhtlensQ%3D%3D (Pubitemid 41697625)
32. WG Ondo T Perkins T Swick, et al. 2008 Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study Arch Neurol 65 1337 40 18852348 10.1001/archneur.65.10.1337
33. P Thaisetthawatkul B Boeve T Ferman, et al. 2004 Autonomic dysfunction in Lewy body dementia Neurology 62 1804 9 15159482 1:STN:280: DC%2BD2c3mtFKqug%3D%3D (Pubitemid 38661739)
34. KL Schoffer RD Henderson K O'Maley JD O'Sullivan 2007 Nonpharmacological treatment, fludrocortisone and domperidone for orthostatic hypotension in Parkinson's disease Mov Disord 22 1543 9 17557339 10.1002/mds.21428 (Pubitemid 47477913)
35. SS Dhruva RF Redberg 2010 Accelerated approval and possible withdrawal of midodrine JAMA 304 2172 3 21081731 10.1001/jama.2010.1695 1:CAS:528: DC%2BC3cXhsVyktL7F This is an interesting article about the developing story regarding the possible withdrawal of midodrine due to failure of the manufacturer to complete postmarketing studies as requested by the FDA
36. W Singer P Sandroni TL Opfer-Gehrking, et al. 2006 Pyridostigmine treatment trial in neurogenic orthostatic hypotension Arch Neurol 63 513 8 16476804 10.1001/archneur.63.4.noc50340
37. W Singer TL Opfer-Gehrking BR McPhee MJ Hilz AE Bharucha PA Low 2003 Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension J Neurol Neurosurg Psychiatry 74 1294 8 12933939 10.1136/jnnp.74.9.1294 1:STN:280:DC%2BD3szps1WqtQ%3D%3D (Pubitemid 37152261)
38. C Shibao LE Okamoto A Gamboa, et al. 2010 Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure Hypertension 56 847 51 20837887 10.1161/HYPERTENSIONAHA.110. 154898 1:CAS:528:DC%2BC3cXhtlSqurfE
39. K Winge CJ Fowler 2006 Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management Mov Disord 21 737 45 16570299 10.1002/mds.20867 (Pubitemid 44028290)
40. JH Wolfgang 2010 Gastrointestinal dysfunction in Parkinson's disease J Neurol Sci 289 69 73 10.1016/j.jns.2009.08.020
41. MR Safarinejad A Taghva B Shekarchi, et al. 2010 Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study Int J Impot Res. 22 325 35 20861846 10.1038/ijir.2010.23 1:CAS:528:DC%2BC3cXhtlWmtbfJ This article establishes an effective treatment important to patients' quality of life
42. WG Ondo C Hunter W Moore 2004 A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease Neurology 62 37 40 14718694 1:CAS:528:DC%2BD3sXhtVWjtrrO (Pubitemid 38082867)
43. JS Reijnders U Ehrt WE Weber, et al. 2008 A systemic review of prevalence studies of depression in Parkinson's disease Mov Disord 23 183 189 17987654 10.1002/mds.21803 (Pubitemid 351311545)
44. A Menza RD Dobkin, et al. 2009 Controlled trial of antidepressants in patients with Parkinson disease and depression Neurology 72 886 892 19092112 10.1212/01.wnl.0000336340.89821.b3 1:CAS:528:DC%2BD1MXisFeksLs%3D Largest reported study to date comparing antidepressant safety and efficacy in PD with depression. Although nortriptyline may have a legitimate role in PD with depression, it is probably best to avoid it or use it with extreme caution in PDD or DLB. SSRI drugs other than paroxetine, which is more sedating than other agents, may be more beneficial in PD patients with cognitive morbidity.
45. S Takahashi K Mizukami, et al. 2009 Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy Psychogeriatrics 9 56 61 19604326 10.1111/j.1479-8301.2009.00292.x
46. JH Friedman 2010 Parkinson's disease psychosis 2010: a review article Parkinsonism Relat Disord. 16 553 60 20538500 10.1016/j.parkreldis.2010.05.004 This is a comprehensive review of the clinical features and management of psychotic symptoms in PD
47. SS Gill SE Bronskill SL Normand 2007 Antipsychotic drug use and mortality in older adults with dementia Ann Intern Med 146 775 86 17548409 (Pubitemid 351650498)
48. A Baskys 2004 Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms J Clin Psychiatry 65 Suppl 11 16 22 15264967
49. WG Ondo R Tintner KD Voung D Lai G Ringholz 2005 Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease Mov Disord 20 958 63 15800937 10.1002/mds.20474 (Pubitemid 41419510)
50. JM Rabey T Prokhorov A Miniovitz E Dobronevsky C Klein 2007 Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration Mov Disord 22 313 8 17034006 10.1002/mds.21116 (Pubitemid 46569682)
51. L Morgante A Epifanio E Spina, et al. 2002 Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease Neurol Sci 23 S89 90 12548358 10.1007/s100720200084 (Pubitemid 35355791)
52. The Parkinson Study Group 1999 Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease N Engl J Med 340 757 63 10.1056/NEJM199903113401003 (Pubitemid 29114294)
53. The French Clozapine Parkinson Study Group 1999 Clozapine in drug-induced psychosis in Parkinson's disease Lancet 353 2041 2 10.1016/S0140-6736(99)00860- 0 (Pubitemid 29271757)
54. JH Friedman RM Berman CG Goetz, et al. 2006 Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease Mov Disord 21 2078 81 17013906 10.1002/mds.21091 (Pubitemid 46140415)